Navigation Links
BioSpecifics Technologies Corp. Added to Russell 3000 and Russell 2000 Indexes
Date:6/29/2009

LYNBROOK, N.Y., June 29 /PRNewswire-FirstCall/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, announced today that it was added to the Russell 3000 and Russell 2000 Indexes effective at the close of the U.S. markets on June 29, 2009. The Russell family of U.S. indexes is reconstituted annually and is designed to be a comprehensive representation of the investable U.S. equity market.

The Russell 3000 Index measures the performance of the largest 3000 U.S. companies representing approximately 98 percent of the investable U.S. equity market. Membership in the Russell 3000 Index results in automatic inclusion in either the large-cap Russell 1000 Index or the widely used small-cap Russell 2000. The Russell 2000 includes approximately 2000 of the smallest securities based on a combination of their market cap and current index membership and is constructed to represent a true small-cap opportunity set.

Russell indexes are widely used by fund managers for index funds and as benchmarks for both passive and active investment strategies.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for three clinical indications: Dupuytren's disease; Peyronie's disease; and frozen shoulder (adhesive capsulitis). Its strategic partner Auxilium Pharmaceuticals, Inc. has announced the acceptance of the Biologic License Application (BLA) and Priority Review by the U.S. Food and Drug Administration for injectable collagenase XIAFLEX(TM) in the treatment of Dupuytren's disease. Pfizer, Inc. is responsible for marketing XIAFLEX product in Europe.

More information about the company may be found on its website at

SOURCE BioSpecifics Technologies Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioSpecifics Technologies Corp. Reports First Quarter 2009 Financial Results
2. BioSpecifics Technologies Corp. Announces FDA Acceptance of Biologics License Application With Priority Review for XIAFLEX(TM) for the Treatment of Dupuytrens Disease
3. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results
4. BioSpecifics Technologies Corp. Announces Listing on NASDAQ Global Market
5. BioSpecifics Technologies Corp. to Present at Piper Jaffray 20th Annual Health Care Conference
6. BioSpecifics Technologies Corp. Announces Appointment of Dr. Matthew Geller to Board of Directors
7. BioSpecifics Technologies Corp. Buys Down Royalties for Peyronies Disease
8. BioSpecifics Technologies Corp. Reports Second Quarter 2008 Financial Results
9. BioSpecifics Technologies Corp. Announces Additional Sales of Stock in Private Placement Offering
10. BioSpecifics Technologies Corp. Announces Sale of Stock in Private Placement Offering
11. BioSpecifics Technologies Corp. Announces Repayment of Outstanding Loan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015  Pharmacyclics, Inc. ... longer-term toxicology studies for its newly developed Bruton,s ... RA, have been completed. The results of these ... Food and Drug Administration. The feedback received from ... the ongoing first-in-human study. Additional preclinical work is ...
(Date:2/27/2015)... 27, 2015 Immunovaccine Inc. (“Immunovaccine”) ... company, today announced that the U.S. Food and ... Track designation and Phase I clinical trials of ... the mutual co-development agreement signed with Gilead Life ... designation for the DPX-Survivac. , “We have been ...
(Date:2/27/2015)... Feb. 27, 2015  Pfenex Inc. (NYSE MKT: PFNX), ... biosimilar therapeutics, today announced that it will be presenting ... on March 2 nd at 3pm PST. Patrick Lucy, ... panel discussing the current state of the biosimilar industry ... For more information on CALBIO 2015 ...
(Date:2/27/2015)...  Steep Hill, the industry leader in cannabis testing ... open a full service medical cannabis quality assurance laboratory ... advanced scientific tools and methodology to the state, for ... currently the only laboratory licensed by the New Mexico ... in order to meet the recently adopted regulatory requirements ...
Breaking Biology Technology:Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3Steep Hill First to Receive Provisional Approval to Establish Laboratory Services for Cannabis Testing in State of New Mexico 2
... Nanotechnology will significantly change virtually every facet of ... opportunity to shape these changes and to ensure that ... and controlled. A new report by former EPA official ... for the next presidential administration and describes the immediate ...
... Calif., July 23 Sangamo,BioSciences, Inc. (Nasdaq: SGMO ... For the second quarter ended June 30, 2008, ... $0.18 per share, compared to a,net loss of $5.2 ... in 2007.,As of June 30, 2008, the company had ...
... to Present Plans for Regaining Compliance - - NASDAQ ... ... Meets All Other NASDAQ Capital Market Initial Listing ... Rule -, TUSTIN, Calif., July 23 Peregrine,Pharmaceuticals, Inc. (Nasdaq: ...
Cached Biology Technology:Nanotech: A regulatory blueprint for the next administration 2Sangamo BioSciences Reports Second Quarter 2008 Financial Results 2Sangamo BioSciences Reports Second Quarter 2008 Financial Results 3Sangamo BioSciences Reports Second Quarter 2008 Financial Results 4Sangamo BioSciences Reports Second Quarter 2008 Financial Results 5Sangamo BioSciences Reports Second Quarter 2008 Financial Results 6Sangamo BioSciences Reports Second Quarter 2008 Financial Results 7Sangamo BioSciences Reports Second Quarter 2008 Financial Results 8Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule 2Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule 3Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule 4
(Date:1/22/2015)... ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to inform its shareholders ... Washington,s Department of Licensing, in the United States, awarded ... for driver,s licenses and identification cards to its subsidiary, Valid ... start in January 2015, with enrollment and card production starting ...
(Date:1/22/2015)... MELBOURNE, Fla. , Jan. 13, 2015  Today, ... wearable technology, launched its crowdfunding campaign on Fundable, ... accelerate the build of production capacity to meet ... Photo - http://photos.prnewswire.com/prnh/20150113/168790 ...
(Date:1/22/2015)... MADISON, Wis. , Jan. 15, 2015  BellBrook ... for drug discovery, announced the launch of a ... of the company,s Transcreener UDP Assay, a high ... enzymes. The new assay will allow for sensitive ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
... National Osteoporosis Foundation, osteoporosis affects more than 2 million ... more have osteopeniaclinically significant low bone density that is ... the University of Missouri-Columbia has found that men engaging ... incidence of osteopeniaa condition resulting in two times the ...
... at the University of Illinois published a discovery that challenged ... which was based on an analysis of ribosomal RNA, ... opened up a new field of study, and established ... To mark the anniversary of this discovery, the university is ...
... of human bones is vastly different than previously believed ... debilitating bone disorders are treated. Researchers from the ... and the BAM Federal Institute of Materials Research and ... stiffness of bone is predominantly due to the presence ...
Cached Biology News:Study shows some athletic men may risk low bone density 2Symposium marks 30th anniversary of discovery of third domain of life 2Symposium marks 30th anniversary of discovery of third domain of life 3Symposium marks 30th anniversary of discovery of third domain of life 4New research on structure of bones raises questions for treatment of osteoporosis 2
... The Fujifilm Life Science FLA-5100 imaging system ... as large as 40 x 46cm at ... microns. This system is especially suitable for ... general array analysis for genomics., Fuji s ...
... and Non-ionic Detergent Removal , ... selective, virtually no cross-reactivity with other proteins ... pellet , Economical new surface technology, ... can often interfere with protein analysis. SurfactAway ...
Physical Form: saline suspension with ethanol Particle Dim: mean particle size 50 μm Matrix: HyperD F. Useful for the removal of detergents from protein samples....
... The Caliper Sciclone ALH 3000 workstation ... diagnostic applications, from Genomic and Proteomic Sample ... Assays. The modular design of the ... options and accessories to perfectly meet the ...
Biology Products: